MedTrace Logo

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

NCT02147834 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-06-11

Study results available
· View outcomes & findings →

Summary

To determine if ranolazine improves angina symptoms at 4 months compared with placebo among patients who are deferred for receiving a Percutaneous Coronary Intervention (PCI) based on the Fractional Flow Reserve (FFR) measurement.

Conditions

  • Angina

Interventions

DRUG

Ranolazine

Ranolazine 500mg tablet 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks

DRUG

Sugar pill

sugar pill manufactured to mimic ranolazine 500mg tablet 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • University of Florida

    collaborator OTHER

  • North Florida Foundation for Research and Education

    lead OTHER

Principal Investigators

  • Anthony A Bavry, MD, MPH · North Florida/South Georgia Veterans Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-03-31
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147834 on ClinicalTrials.gov